WCN26-5467 ASPIrin to Reduce Events in Dialysis (ASPIRED) trial: a pragmatic, registry-based, double-blind randomized clinical trial

Read full text Summarise with VIRAT
Authors: Li Fan, Muh Geot Wong, Wei Chen, Zhiming Ye, Meg Jardine, Sunil Badve, L Billot, Ning Tan, Helen Monaghan, Menghua Chen, Sarah E. Coggan, Sradha S. Kotwal
+3 more Guixian Ma, Vlado Perkovic, Xueqing Yu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Individuals with kidney failure receiving dialysis have a substantially greater risk of suffering cardiovascular (CV) events than the age- and gender-matched general population. Although aspirin is an effective antiplatelet agent commonly used for primary and secondary CV prevention, data regarding its role in the dialysis population is limited to a few post hoc analyses of larger trials, partly due to the paradoxical relationship between thromboembolic and bleeding risk in patients on dialysis.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Dialysis and Renal Disease Management Atrial Fibrillation Management and Outcomes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104237–104237
Publication date
25 March 2026
Language
EN